

The RT3S project: towards safer vascular stenting

A. Chiarini (SCS), C.Silvestro (Medtronic)

Outline


- ❑ Medtronic, Inc.
- ❑ Vascular Stenting
- ❑ RT3S Project
 - Overview
 - Modelling aspects
 - Response surface
- ❑ Results
- ❑ Validation
- ❑ Conclusions

Medtronic, Inc.

Medtronic, Inc. Minnesota (US) based, world's largest medical technology company and a Fortune 500 company

❑ Business units:

- CRDM (cardiac rhythm disease management)
- Diabetes
- Neuromodulation
- Spinal
- **Cardiovascular**
- Surgical technologies



Spinal reconstructions



MRI-compatible pacemakers



Neurostimulation



Cervical disks replacement


Including **Endovascular Therapies** business unit
Providing minimally invasive solutions for the treatment of cardiovascular disease

Endovascular Therapies R&D


- ❑ Based in Santa Rosa (California)
- ❑ ~140 engineers and technicians
- ❑ Locations in USA, Frauenfeld (CH), Brescia (IT)
- ❑ > 50% of group has Master's Degree, Several PhD's
- ❑ > 12.5% of revenue invested in R&D

On the market:

Stents



Peripheral angioplasty balloons



Aortic and thoracic stent grafts




Balloon and stent technologies




Endovascular Therapies R&D

Patient-oriented, strictly regulated Product Development Process



The problem: stent fatigue fracture in peripheral arteries



- ❑ Stent fracture leads to in-stent restenosis.
- ❑ By computing the risk of stent fatigue fracture while planning the intervention, a warning can be given when the combination of patient-specific and surgery-specific factors create fracture risks, thus drastically reducing the incidence of this important complication.

Clinical trials


- The analyzed trials show a broad range of stent fracture rate
- All the trials underline the importance of fractures investigation in the SFA district

Trial	Number of implanted stents	FRACTURE RATE	6-month Restenosis rate (+)	Restenosis rate (12 MONTHS)
SIROCCO I	79	27 % (6 months)	11.5 % (**)	NA
SIROCCO I+II	177	17 % (6 months) 22 % (24 months)	4.6 %	22% (24 months)
VIENNA ABSOLUTE	106	2 % (6 months)	25 %	37 %
FAST	136	12 % (12 months)	NA	31.7 %
FESTO	261	24,5 % (11 months)	NA	NA
Dick et al., 2009	54	NA	18.2 %	34.4 %



(+) Stenosis of at least 50% of luminal diameter (duplex US) (*) 10.7-month follow up
 (**) from angiography

Geometry Dependence [FESTO]

STENT FRACTURES



Stent fractures rate shows clear dependence on stent length



The RT3S approach


MEDICAL INDUSTRY



WP9

Numerical simulations

Reproduce *in-vivo* loading conditions of implanted stents



WP2 & WP3




Integration

WP8

Software Development

Integrate device properties with numerical simulations, providing interface



WP4 & WP5



WP7

Training

Develop training SW for medical students

Clinical

Test the software tool & provide clinical insight



WP6


Modelling: blood vessel and plaque

Definition of anatomical and stent design parameters for the probabilistic model

- vessel diameter : D_V
- residual lumen : $RL = D_P / D_V$
- plaque length : L_P
- plaque sharpness : S


$$y(x) = D_V \cdot (1-RL) \cdot [\sin(\pi \cdot x / L_P)]^S$$

Plaque profile $y(x)$




- plaque asymmetry : $As = 2e_P / (D_V - D_P)$
- vessel curvature : $\chi = 1 / R_C$

$y(x)$ can be deformed to match the vessel curvature χ and to introduce a radial asymmetry As




Stenotic vessel model



Modelling: blood vessel and plaque

Creation of parametric anatomical models




$D_V = 5.7 \text{ mm}$
0

$\chi = 0$
 $S = 1.5$

$RL = 0.2$

$L_p = 45 \text{ mm}$

$As =$



$D_V = 5.7 \text{ mm}$

$\chi = 0.008 \text{ mm}^{-1}$

$RL = 0.2$

$L_p = 45 \text{ mm}$

$As = 0$



$D_V = 5.7 \text{ mm}$

$\chi = 0$

$RL = 0.2$

$L_p = 25 \text{ mm}$

$As = 0.8$



$D_V = 5.7 \text{ mm}$

$\chi = 0$

$RL = 0.2$

$L_p = 25 \text{ mm}$

$As = 0.8$

Modelling: blood vessel and plaque

Creation of parametric anatomical models

Range of parameters for probabilistic simulations

Model	Parameter	Symbol	Range of values
Stenotic vessel	Vessel diameter	D_v	4-7 mm
	Vessel curvature	χ	0-0.008 mm ⁻¹
	Residual lumen	RL	0.05-0.35
	Plaque length	L_p	40-190 mm
	Plaque asymmetry	As	0 - 1
	Plaque sharpness	S	0.1- 1

Modelling: stent

Definition of anatomical and stent design parameters for the probabilistic model

Stent models

For the stent models, a parametric description is not used.

Few different geometries are considered for the stent layout, corresponding to different design strategies adopted by different companies. These cell geometries may be considered as representative of the geometries adopted by most stent producers.


A number of diameters and length are modeled for each geometry, taking into account typical dimension of peripheral vessels and plaques.

Modelling: stent


Creation of stent models

→ Simulated stents


Maris Plus - Medtronic Invatec



S.M.A.R.T. CONTROL – Cordis (Johnson and Johnson Co)



Absolute Pro - Abbott Vascular



COMPANY	PRODUCT	DIAMETER [mm]	LENGTH [mm]	Number of modeled stents
ABBOTT	Absolute Pro	5 ; 6 ; 7 ; 8	60; 80; 120; 150; 170 (100+80); 200 (150+60)	24
CORDIS (Johnson and Johnson Co)	S.M.A.R.T CONTROL	6 ; 7 ; 8	60; 80; 100; 130 (100+40); 170 (100+80); 190 (100+100)	18
MEDTRONIC INVATEC	MARIS PLUS	6 ; 7 ; 8	60; 80; 120; 150; 170 (100+80); 200 (150+60)	18



Different sizes (diameter and length) are investigated for each geometry, leading to **60 stents** to be simulated and 60 response surfaces to be constructed

Modelling: stent


In vitro characterization of stent materials

→ Measurements of pseudoelastic properties of Nitinol for peripheral stents

Samples laser cut from Nitinol tubes, subjected to the same treatments of a stent



Temperature control system - water at 37° C




Response Surface Technologies

- ❑ **Design of Experiments and Interpolation Techniques**
 - Optimal Space Filling DOE to get an uniform grid in the Cartesian Product of variation ranges
 - Kriging interpolation
- ❑ 3D stent fatigue simulation is very expensive. 5-10 days on 8 cores for one single solve
- ❑ 3D stent fatigue simulation is not robust. Convergence issues due to highly distorted elements.
- ❑ Mesh Morphing can't be applied due too large variations of shape parameters
- ❑ Single solve poor scalability due to large contact zones
- ❑ Perfect scalability of multiple solves
- ❑ Design Exploration of Solution Fields to get more than an interpolation of scalar values

Geometry Partition

The finite element mesh used for angioplasty simulation



The finite element mesh to review angioplasty response surface results corresponding to geometry partition (1 node = 1 vertex and 1 element = 1 solid)

Angioplasty Output Parameters

❑ Residual Stenosis

- Scalar value computed after release of the balloon
- Field of displacements results on vertices corresponding to each simulation step

❑ Axial reaction Force

- Scalar value computed at the axial stretching step

❑ External Pressure

- Scalar value computed at the angioplasty step



❑ Maximum first principal stress and maximum Von Mises stress

- Scalar values computed at the angioplasty step
- Field of stresses on solids


Parametric model

25	⌚ P27	Commands (APDL) ARG2	0.75
26	⌚ P28	Commands (APDL) ARG3	-0.75
27	⌚ P5	plaque_length	50
28	⌚ P16	residual_lumen	0.8
29	⌚ P17	asymmetry	0
30	⌚ P18	sharpness	0.8
31	⌚ P19	tb	0.56

Geometry with Asymmetry = 0



One-click update



Geometry update

Model update:
Mesh

Setup update:
boundary conditions
(loads,...) and
Analysis Settings


Job run is
finished

Angioplasty Response Surface

- ❑ Around 450 Angioplasty solves launched in parallel on the CINECA PLX Cluster
- ❑ 2 sets of design points
 - Learning set to build the response surface
 - Validation set to compare interpolated results and reference results
- ❑ Parameterization of solution fields based on
 - Singular Value Decomposition of the list of vectors
 - Approximation of modes coefficients using Kriging interpolation
 - Scalar output parameters computed from solution fields
- ❑ Variation of the number of learning points
- ❑ Variation of the number of modes
- ❑ Validation using scalar output parameters accuracy

From Angioplasty to Fatigue

- The Fatigue models use 2 input parameters which are computed from Angioplasty results:
 1. Inner Diameter of the tube using RS1 and RS4 on the nodes corresponding to the central section
 2. Young's Modulus of the tube computed from the axial reaction force (RS7) and displacement results of RS4






Tube (equivalent to plaque + artery)

Stent (initial position)

Response Surface Validation

Results on Residual Stenosis

Variation from 0.13 to 0.83
Mean Value = 0.42




Validation using the full set of points (around 450)

Validation

3D deterministic stent simulations for the fatigue-life predictions

→ First simulations of fatigue loading on the stent



Validation

3D deterministic stent simulations for the fatigue-life predictions

→ First validation of the stent models through *in vitro* test (static)

Tensile test (stretching at 40%)
Compression test (shortening at 20%)




a)



Experimental Setup

Prediction of stent axial stiffness



Comparison of stent axial stiffness and deformed configurations

Conclusions

- ❑ We presented a CAE workflow aimed at predicting failure risk for a stent when deployed in a pathological patient.
- ❑ The presented workflow involves time-consuming simulations and it heavily exploits response surface technologies and HPC resources to get data for generating a failure risk prediction.

Acknowledgements



Medtronic



POLITECNICO
DI MILANO



SCS
SuperComputingSolutions



Medtronic



Disclaimer

- ❑ RT3S is a project co-funded by the European Commission Seventh FRAMEWORK PROGRAMME
- ❑ The research reported upon in this presentation has either directly or indirectly been supported by the European Commission, DG CONNECT, Brussels.
- ❑ The results, analyses and conclusions derived there from reflect solely the views of its authors and of the presenter.
- ❑ The European Community is not liable for any use that may be made of the information contained therein.